MARKET

ASLN

ASLN

Aslan Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.830
-0.080
-2.75%
Closed 17:59 07/29 EDT
OPEN
2.900
PREV CLOSE
2.910
HIGH
2.910
LOW
2.800
VOLUME
205.28K
TURNOVER
--
52 WEEK HIGH
6.75
52 WEEK LOW
1.260
MARKET CAP
196.74M
P/E (TTM)
-6.7461
1D
5D
1M
3M
1Y
5Y
Were Hedge Funds Right About ASLAN Pharmaceuticals Limited (ASLN)?
Is ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduat...
Insider Monkey · 2d ago
3 Biotech Stocks Wall Street Predicts Will Rally by More Than 170%
StockNews.com · 07/22 10:22
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers
Benzinga · 07/19 21:30
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers
Benzinga · 07/15 20:34
Clene, Inhibikase Therapeutics leads healthcare gainers; IMV, Tempest Therapeutics among major losers
Gainers: Clene (CLNN) +8%, Inhibikase Therapeutics (IKT) +7%, ASLAN Pharmaceuticals (ASLN) +5%, Doximity (DOCS) +5%.Losers: IMV (IMV) -26%, Tempest Therapeutics (TPST) -25%, Sonoma Pharmaceuticals (SNOA) -23%, Immunic (IMUX) -18%, Virpax Pharmaceuticals (V...
Seekingalpha · 07/15 15:02
ASLAN Pharmaceuticals Draws Down Full $20 Million Tranche to Advance Autoimmune Gastrointestinal Disease Treatment
MT Newswires · 07/14 06:53
The Daily Biotech Pulse: Equillium Issues Positive Regulatory Update, Biogen In-Licenses Multiple Sclerosis Drug, Aridis Releases COVID-19 Antibody Cocktail Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 12)
Benzinga · 07/13 12:05
ASLAN Pharma Secures Debt Funding Of $45M To Support ASLAN003 Development
Benzinga · 07/13 12:03
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ASLN. Analyze the recent business situations of Aslan Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ASLN stock price target is 8.00 with a high estimate of 8.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 46
Institutional Holdings: 28.06M
% Owned: 40.37%
Shares Outstanding: 69.52M
TypeInstitutionsShares
Increased
5
725.22K
New
29
21.57M
Decreased
5
966.79K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.49%
Pharmaceuticals & Medical Research
-0.31%
Key Executives
Chairman/Director
Andrew Howden
Chief Executive Officer/Director
Carl Firth
Vice President - Finance
Kiran Asarpota
Vice President
Alison Ward
Other
Kenneth Kobayashi
Director
Jun Wu
Independent Director
Robert Hoffman
Independent Director
Kathleen Metters
Independent Director
Chin-Feng Sun
No Data
About ASLN
ASLAN Pharmaceuticals Limited is a clinical-stage immunology focused biopharmaceutical company. The Company is engaged in developing treatments to transform the lives of patients. The Company is developing ASLAN004, an antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, an oral inhibitor of dihydroorotate dehydrogenase (DHODH), which is being developed for autoimmune disease. The Company's ASLAN004 is a fully human monoclonal antibody targeting the IL-13 receptor a1 subunit (IL-13Ra1). By targeting IL-13Ra1, which forms the Type II receptor complex with IL-4Ra, ASLAN004 inhibits signaling of both interleukin 4 (IL-4) and interleukin 13 (IL-13). IL-4 and IL-13 are central to triggering symptoms of allergy in atopic dermatitis, such as redness and itching of the skin, as well as asthma symptoms such as shortness of breath, wheeze and cough.

Webull offers kinds of Aslan Pharmaceuticals Ltd (ADR) stock information, including NASDAQ:ASLN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ASLN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ASLN stock methods without spending real money on the virtual paper trading platform.